SCHEMBL2172684

SCHEMBL2172684

COc1cccc(CNC(=O)c2coc(CN3C(=O)c4ccccc4C3=O)n2)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 3/20 0.49
HPGD P15428 3/20 0.49
THRB P10828 2/20 0.48
ROCK2 O75116 1/20 0.46
ROCK1 Q13464 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 3/20 0.45
LMNA P02545 2/20 0.45
TP53 P04637 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAOB P27338 1/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.44
KLKB1 P03952 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172393 0.92 MEN1 (0.56) MEN1KMT2AALDH1A1HPGDNPC1
SCHEMBL2174308 0.76 CACNA1G (0.48) MEN1KMT2AHPGDKDM4ELMNA
SCHEMBL2171430 0.75 MEN1 (0.58) MEN1KMT2AALDH1A1HPGDNPC1
SCHEMBL2173353 0.73 HIF1A (0.52) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL2173835 0.73 NPC1 (0.46) MEN1KMT2AALDH1A1ROCK2ROCK1
SCHEMBL2171500 0.71 MAPT (0.51) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL2171878 0.69 HIF1A (0.50) MEN1KMT2AALDH1A1HPGDTHRB
SCHEMBL2174888 0.69 MAPT (0.59) MEN1KMT2AALDH1A1HPGDROCK2
SCHEMBL20525369 0.69 THRB (0.75) MEN1KMT2AALDH1A1THRBLMNA
SCHEMBL29131731 0.68 MEN1 (0.57) MEN1KMT2AALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
EP-1730128-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-12-13 EP disclosed
WO-2005097765-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 MEN1 3194/4885KMT2A 973/4885ALDH1A1 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.